Need professional-grade analysis? Visit stockanalysis.com
$43.92B
19.58
24,535
1.43%
Haleon plc (HLNCF) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at $4.82, up 0.94% from the previous close.
Over the past year, HLNCF has traded between a low of $4.32 and a high of $5.75. The stock has lost 4.7% over this period. It is currently 16.3% below its 52-week high.
Haleon plc has a market capitalization of $43.92B, with a price-to-earnings ratio of 19.58 and a dividend yield of 1.43%.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Side-by-side comparison against top Healthcare peers.